Comparison of empagliflozin and sitagliptin therapy on myocardial perfusion reserve in diabetic patients with coronary artery disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparison of empagliflozin and sitagliptin therapy on myocardial perfusion reserve in diabetic patients with coronary artery disease

Published:2021-05-19 Issue:9 Volume:42 Page:972-978
ISSN:0143-3636
Container-title:Nuclear Medicine Communications
language:en
Short-container-title:

Author:

Oh Minyoung,Choi Joon Ho,Kim Seon-Ok,Lee Pil Hyung,Ahn Jung-Min,Lee Seung-Whan,Moon Dae Hyuk,Lee Cheol Whan

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Radiology Nuclear Medicine and imaging,General Medicine

Reference39 articles.

1. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.;Zinman;N Engl J Med,2015

2. Canagliflozin and cardiovascular and renal events in type 2 diabetes.;Neal;N Engl J Med,2017

3. Dapagliflozin and cardiovascular outcomes in type 2 diabetes.;Wiviott;N Engl J Med,2019

4. Dapagliflozin in patients with heart failure and reduced ejection fraction.;McMurray;N Engl J Med,2019

5. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.;Zelniker;Lancet,2019

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative effects of canagliflozin and sitagliptin in chronically ischemic myocardium;Vessel Plus;2024-01-12

2. Sitagliptin therapy improves myocardial perfusion and arteriolar collateralization in chronically ischemic myocardium: A pilot study;Physiological Reports;2023-06

3. Associations of cardiovascular and diabetes-related risk factors with myocardial perfusion reserve assessed by 201Tl/99mTc-tetrofosmin single-photon emission computed tomography in patients with diabetes mellitus and stable coronary artery disease;The International Journal of Cardiovascular Imaging;2023-06-01

4. Design expert software assisted development and evaluation of empagliflozin and sitagliptin combination tablet with improved in-vivo anti-diabetic activities;Heliyon;2023-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3